Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI Rating ESG 2020
Fri, 25/09/2020 - 14:25
0 min
Download related document
Select rating
Give ROVI Rating ESG 2020 1/5
Give ROVI Rating ESG 2020 2/5
Give ROVI Rating ESG 2020 3/5
Give ROVI Rating ESG 2020 4/5
Give ROVI Rating ESG 2020 5/5
No votes yet
Related
ROVI leads the BioElast Consortium approved in the 2021 Call for Projects in...
Madrid: 28 of December 2022 The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (...
1 min
28/12/2022
ROVI launches an initiative to develop solutions that improve sustained-release...
Sustained-release drug delivery is a field where significant progress is being made that increases the efficacy of the medicines, improves...
3 min
24/11/2022
2022 Capital Markets Day presentation
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION (COMISIÓN NACIONAL DEL MERCADO DE VALORES) Madrid, 23 November 2022 In...
1 min
23/11/2022
See More
Email
Facebook
Twitter
LinkedIn